Inflammatory Response to CSII Catheters in a Tummy Tuck Model
NCT03298295 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-08-01
Summary
In insulin pump therapy, insulin is continuously infused into the subcutaneous adipose tissue via a continuous subcutaneous insulin infusion (CSII) catheter using a basal/bolus pattern. Unfortunately, insulin absorption from the tissue surrounding a CSII catheter can be slow, variable, and unreliable. It is recommended to replace CSII catheters after 2 to 3 days of use. Frequently changing the injection site can be tedious and moreover leads to scarring, while reusing the same injection site can lead to medical complications such as lipohypertrophy. CSII catheters are manufactured from both steel and Teflon and use of either of these materials is based on personal preference/experience rather than scientific, empirical data. We hypothesize that the inflammatory response to CSII catheters is a major contributor to variable insulin absorption and that this response is significantly different between materials and catheters shapes. In order to develop CSII catheters with an extended life-time up to 7 days, we need to better understand the inflammatory response caused by the introduction and maintenance of a CSII catheter into the subcutaneous adipose tissue. This study is a pilot study in humans scheduled for elective plastic surgery where a large skin flap is removed from the abdominal region. Teflon and steel CSII catheters will be inserted into the abdomen 7, 4, and 3 days prior to surgery. This study design allows for the removal of tissue plugs surrounding CSII catheters without causing additional scarring for the patient.
Conditions
Interventions
- DEVICE
-
Continous Subcutaneous Insulin Infusion Catheter
Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
Sponsors & Collaborators
-
Medical University of Graz
lead OTHER
Principal Investigators
-
Lars-Peter Kamolz, MD Prof · Medical University of Graz
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-02-01
- Primary Completion
- 2023-05-09
- Completion
- 2024-12-31
Countries
- Austria
Study Locations
More Related Trials
-
Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")
NCT04398030 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously
NCT01061216 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Compare Intraperitoneal Insulin to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus
NCT00286962 ·Status: COMPLETED ·Phase: PHASE3
-
Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue for the Treatment of Type-1 Diabetic Patients
NCT00812591 ·Status: COMPLETED ·Phase: NA
-
Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes
NCT00922649 ·Status: COMPLETED ·Phase: NA
-
Expanding Coverage of Continuous Subcutaneous Insulin Infusion in Pediatric Patients With Diabetes
NCT00829062 ·Status: WITHDRAWN ·Phase: NA
-
CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Cross-Sectional Study
NCT02258945 ·Status: COMPLETED
-
Individual Patient Data Meta-analysis of CSII vs. MDI in Type 2 Diabetes
NCT02910141 ·Status: COMPLETED
-
Study on the Use of the Insulin Pump Tandem X:2 With Control IQ Algorithm - Update
NCT05118945 ·Status: COMPLETED
-
Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion
NCT01557907 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy
NCT01104142 ·Status: COMPLETED
-
Evaluation of a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Adipose Tissue of Diabetic Patients
NCT00813410 ·Status: COMPLETED ·Phase: NA
-
Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy
NCT01574508 ·Status: UNKNOWN ·Phase: PHASE4
-
Continuos Subcutaneous Insulin Infusion in Italy
NCT02620917 ·Status: COMPLETED
-
BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study
NCT02662842 ·Status: COMPLETED
-
A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
NCT00502138 ·Status: COMPLETED ·Phase: PHASE4
-
"FEXIS": (Feasibility of an Extended Wear CSII Set in Participants With T1DM)
NCT04503564 ·Status: COMPLETED ·Phase: NA
-
Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate
NCT00569452 ·Status: COMPLETED ·Phase: NA
-
Hyaluronidase Effect on Infusion Set Life
NCT02199028 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of RT-CGMS in Patients With Type 1 Diabetes Mellitus Treated With an Implantable Pump
NCT00501072 ·Status: COMPLETED ·Phase: NA
-
Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered
NCT03838783 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes
NCT01029444 ·Status: TERMINATED ·Phase: PHASE3
-
Effect of CSII and CGM on Progression of Late Diabetic Complications
NCT01454700 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set
NCT02687256 ·Status: COMPLETED ·Phase: PHASE1
-
Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults
NCT02382536 ·Status: COMPLETED